Abstract
Novel therapeutic approaches targeting signaling pathways involved in cell proliferation, apoptosis, angiogenesis and metastasis have been under clinical development. Of many potential targets in adult solid tumors, the epidermal growth factor receptor (EGFR) has been the most extensively studied since its over-expression has been observed in several common solid tumors. However, the insurgence for resistance to drugs targeting the EGF-receptor has been described. The understanding of the mechanisms which are responsible of resistance to EGFR inhibitors could lead to the development of improved strategies to integrate anti-EGFR therapies. In this review, we will describe the latest new strategies developed to optimize the therapeutic effects of EGFR inhibitors, by exploring combinations with other molecular targeted approaches including other erbB family member inhibitors, drugs with different structure and mechanism of action, other tumor cell-directed signal transduction inhibitors, anti-angiogenic treatment modalities, and the use of broad spectrum EGFR tyrosine kinase inhibitors.
Keywords: EGFR, angiogenesis, combination treatment, targeted therapy
Current Cancer Therapy Reviews
Title: Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Volume: 3 Issue: 2
Author(s): Floriana Morgillo, Erika Martinelli, Teresa Troiani, Giampaolo Tortora and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, angiogenesis, combination treatment, targeted therapy
Abstract: Novel therapeutic approaches targeting signaling pathways involved in cell proliferation, apoptosis, angiogenesis and metastasis have been under clinical development. Of many potential targets in adult solid tumors, the epidermal growth factor receptor (EGFR) has been the most extensively studied since its over-expression has been observed in several common solid tumors. However, the insurgence for resistance to drugs targeting the EGF-receptor has been described. The understanding of the mechanisms which are responsible of resistance to EGFR inhibitors could lead to the development of improved strategies to integrate anti-EGFR therapies. In this review, we will describe the latest new strategies developed to optimize the therapeutic effects of EGFR inhibitors, by exploring combinations with other molecular targeted approaches including other erbB family member inhibitors, drugs with different structure and mechanism of action, other tumor cell-directed signal transduction inhibitors, anti-angiogenic treatment modalities, and the use of broad spectrum EGFR tyrosine kinase inhibitors.
Export Options
About this article
Cite this article as:
Morgillo Floriana, Martinelli Erika, Troiani Teresa, Tortora Giampaolo and Ciardiello Fortunato, Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618434
DOI https://dx.doi.org/10.2174/157339407780618434 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism Modulation of the Peripheral and Central Inflammatory Responses by a-Melanocyte Stimulating Hormone
Current Protein & Peptide Science Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology The Targets of Curcumin
Current Drug Targets Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Sialic Acid and the Central Nervous System: Perspectives on Biological Functions, Detection, Imaging Methods and Manipulation
CNS & Neurological Disorders - Drug Targets The Role of the Complex USP1/WDR48 in Differentiation and Proliferation Processes in Cancer Stem Cells
Current Stem Cell Research & Therapy Antitumor Activity and Structure-Activity Relationship of Diterpenoids with a Dehydroabietyl Skeleton
Combinatorial Chemistry & High Throughput Screening FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Convection-Enhanced Delivery: Neurosurgical Issues
Current Drug Targets Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets